OmniAb, Inc. Common Stock OABI

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

• The Motley Fool 29 ago

  AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

  The article compares AbbVie and Eli Lilly as pharmaceutical investment options for 2026. AbbVie focuses on immunology and neuroscience with revenue of $61.2B and faces patent expiration risks, while Eli Lilly is experiencing explosive 45% revenue growth driven by its GLP-1 drugs (Mounjaro and Zepbound) with projected 2026 revenue of $85.2B. Despite Eli Lilly's higher valuation, the article recommends it for long-term investors due to the sustained demand and lifecycle nature of its metabolic therapies.

  

• GlobeNewswire Inc. 6 jul

  VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines

  VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The company is actively pursuing partnerships and reported strong industry interest in its novel BiTAC technology.